Thai investors now can trade in real-time during local market hours using baht without overseas accounts, while also benefiting from capital gains tax exemptions.

BEIJING, Dec. 29, 2025 /PRNewswire/ — Today, China Asset Management Co. (ChinaAMC) partnered with Thai securities firm InnovestX Securities to list Depository Receipts (DRs) linked to the “ChinaAMC CSI 300 ETF” and the “ChinaAMC STAR 50 ETF” on the Stock Exchange of Thailand (SET), enabling Thai investors access to a basket of China’s core assets and hard-core technologies. 

This marks the first time that ETFs listed on the Shanghai Stock Exchange (SSE) have entered an overseas market through a DR structure, and represents another milestone in deepening capital market cooperation between China and Thailand under the Belt and Road Initiative.

The simultaneous listing of these two flagship ETFs in Thailand also fully reflects the local market’s strong interest in allocating to high-quality Chinese assets and their confidence toward growth prospects of China’s technology sector.

In June, ChinaAMC collaborated with Thailand’s leading asset manager BBL Asset Management to launch the Southeast Asian nation’s first feeder fund channels to China’s A500 ETF, marking the first overseas introduction of China’s broad-based A500 index.

This July also witnessed ChinaAMC’s introduction of China Global Vision Fund to Thai investors, via partnership with Thailand’s First Plus Asset Management. Notably, ChinaAMC has secured the first fully discretionary mandate among onshore Chinese managers to run a Thai-domiciled fund. The fund is dedicated to investing in leading Chinese firms expanding internationally, enabling Thai investors to capitalize on the structural trend of China companies going global.

From the A500, China Global Vision Fund to the STAR 50 and CSI 300 indices, ChinaAMC has continued to expand overseas investors’ “China asset allocation toolkit” through forward-looking planning and efficient execution.

Easy Access to China’s “core assets “+ “hard tech”

A key highlight of this issuance is that it offers global investors a wrap-up of China’s “hard tech” strength besides core assets.

Unlike traditional broad-based or general growth indices, the STAR 50 Index brings together leading companies in China’s strategic emerging industries such as semiconductors, high-end equipment, and biomedicine. The listing of the ChinaAMC STAR 50 ETF DR fills a gap in the Southeast Asian market for investing in China’s “hard tech” sector. This not only allows Thai investors to directly benefit from China’s technological transformation but also collectively demonstrates the international capital market’s high recognition of China’s latest achievements in core technology breakthroughs, semiconductor supply chain independence and technological self-reliance.

At the same time, the ChinaAMC CSI 300 ETF, widely regarded as a barometer of the Chinese economy, is also being listed in Thailand through the DR structure, providing international investors with a channel for one-click access to China’s core high-quality assets. The simultaneous listing of these two products creates a strategy of “core assets + hard-core technology.”

ChinaAMC: Leading Chinese Asset Managers’ “Go Global” drive

As a pioneer in China asset management industry’s “go global” drive, ChinaAMC has always been at the forefront of promoting the internationalization of Chinese assets, boasting exceptional index investment management capabilities and extensive cross-border business experience.

This project leverages efficient connectivity mechanisms to build a highly innovative cross-border ecosystem. InnovestX Securities purchases the underlying ETFs in the Hong Kong market through the “Northbound ETF Connect” scheme and then issues DRs in Thailand. ChinaAMC provides the underlying high-quality asset management services, while InnovestX is responsible for local issuance and market-making.

This model efficiently connects the markets of Mainland China, Hong Kong, and Thailand. Thai investors can trade in real-time during local market hours using Thai baht without overseas accounts, while also benefiting from policy incentives such as capital gains tax exemptions. This not only significantly enhances the convenience of cross-border investment but also facilitates a continuous inflow of overseas medium- to long-term capital into the SSE market, showcasing a new chapter in the high-level opening-up of China’s capital markets.

About ChinaAMC

Founded in April 1998, China Asset Management Co., Ltd. (ChinaAMC) has grown to be one of the largest asset managers in China, with total AUM exceeding RMB3.2 trillion (US$449.5billion) as of Sept 30, 2025. It positioned itself as a full-service and versatile asset management platform that operates across asset classes, industries and regions. ChinaAMC has been China’s largest equity ETF provider for 20 consecutive years (2005-2024).

Source: ChinaAMC. AUM includes subsidiaries. Data as of Sept 30, 2025.

Disclaimer

Investment involves risk, including possible loss of principal. The information contained herein is for reference only and reflects prevailing market conditions and our judgment as of the release date, which are subject to change without further notice.

SUZHOU, China, Dec. 29, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor) in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment of advanced cervical cancer (Study Number: JSKN033-202), has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

Cervical cancer is the most common gynecological malignancy and the fourth leading cause of cancer-related deaths among women. Patients with early-stage disease often experience recurrence or metastasis within two years after treatment, while those with advanced disease have a poor prognosis, with a five-year survival rate of less than 20%. Currently, platinum-based (cisplatin or carboplatin) chemotherapy combined with bevacizumab represents the guideline-recommended first-line standard of care. Although immune checkpoint inhibitors have also achieved breakthrough progress, tumor heterogeneity in cervical cancer still leads to suboptimal responses in some patients, highlighting a clear unmet clinical need.

In recent years, multiple clinical studies have confirmed the synergistic potential of combining ADCs with immunotherapy and anti-angiogenic agents. As a first-in-class co-formulation of ADC and immune checkpoint inhibitor, JSKN033 leverages a dual mechanism of action, combining targeted tumor killing with immune activation. In early-stage clinical studies, JSKN033 monotherapy has demonstrated promising efficacy and a manageable safety profile in patients with cervical cancer who have failed standard therapies.

JSKN033-202 is an open-label, multicenter phase II clinical trial designed to evaluate the safety, efficiency and pharmacokinetics (PK)/pharmacodynamics (PD) of JSKN033 in combination with platinum-based chemotherapy, with or without bevacizumab, as first-line treatment for patients with advanced cervical cancer. All patients will receive treatment with JSKN033 plus either cisplatin or carboplatin, with or without bevacizumab, with the choice of platinum agent and the use of bevacizumab determined by the investigator based on individual patient circumstances. The initiation of this study is expected to provide an innovative and convenient treatment option for patients with advanced cervical cancer.

About JSKN033

JSKN033 is the global first high-concentration subcutaneous formulation, combining the ADC (JSKN003) with PD-L1(Envafolimab), which is independently developed by the Company. JSKN003 is developed by site-specific conjugation to the Fc glycans of Anbenitamab (KN026), resulting in a homogeneous and stable ADC with a drug-to-antibody ratio (DAR) of 4. JSKN003 binds to two HER2 epitopes on tumor cells and release topoisomerase I inhibitors through cellular endocytosis, exerting anti-tumor effects. Envafolimab is a Fc fusion protein consisting of humanized anti-PD-L1 single domain antibody and human IgG1 Fc fragment, which has been approved by Chinese authorities as the global-first subcutaneous injection PD-(L)1 inhibitor in November 2021.

JSKN033 combines the benefits of immunotherapy and ADCs while enhancing safety and convenience through subcutaneous administration.

Currently, Phase I/II clinical trials of JSKN033 for the treatment of solid tumors is being conducted in China and Australia. The IND application for the Phase II clinical study of JSKN033 in combination with chemotherapy as first-line treatment for advanced cervical cancer has been accepted by the CDE.

About Alphamab Oncology

Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达^®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.

• XPENG-PKU Research Breakthrough: XPENG, in collaboration with Peking University, has developed FastDriveVLA—a novel visual token pruning framework that enables autonomous driving AI to “drive like a human” by focusing only on essential information, achieving a 7.5x reduction in computational load.
• Top-Tier AI Recognition: The research has been accepted by AAAI 2026, one of the world’s premier AI conferences, which had a highly selective acceptance rate of just 17.6% this year.
• Accelerating L4 Autonomy: This achievement underscores XPENG’s full-stack capabilities in AI-driven mobility and advances the industry toward efficient, scalable deployment of next-generation autonomous driving systems.

GUANGZHOU, China, Dec. 28, 2025 /PRNewswire/ — XPENG, in collaboration with Peking University, has had its paper “FastDriveVLA: Efficient End-to-End Driving via Plug-and-Play Reconstruction-based Token Pruning” accepted by AAAI 2026, one of the world’s top conferences in artificial intelligence. AAAI 2026 received 23,680 submissions, with only 4,167 papers accepted, an acceptance rate of just 17.6%.

The paper introduces FastDriveVLA, an efficient visual token pruning framework specifically designed for end-to-end autonomous driving Vision-Language-Action (VLA) models. This work offers a new approach to visual token pruning by enabling AI to “drive like a human”, focusing only on essential visual information while filtering out irrelevant data.

As AI large models evolve rapidly, VLA models are being widely adopted in end-to-end autonomous driving systems due to their strong capabilities in complex scene understanding and action reasoning. These models encode images into large numbers of visual tokens, which serve as the foundation for the model to “see” the world and make driving decisions. However, processing large numbers of tokens increases computational load onboard the vehicle, impacting inference speed and real-time performance.

While visual token pruning has been recognized as a viable method to accelerate VLA inference, existing approaches, whether based on text-visual attention or token similarity, have shown limitations in driving scenarios. To address this, XPENG and PKU developed FastDriveVLA, a novel reconstruction-based token pruning framework inspired by how human drivers focus on relevant foreground information while ignoring non-critical background areas.

The method introduces an adversarial foreground-background reconstruction strategy that enhances the model’s ability to identify and retain valuable tokens. On the nuScenes autonomous driving benchmark, FastDriveVLA achieved state-of-the-art performance across various pruning ratios. When the number of visual tokens was reduced from 3,249 to 812, the framework achieved a nearly 7.5x reduction in computational load while maintaining high planning accuracy.

This is the second time this year that XPENG has been recognized at top-tier global AI conference. In June, XPENG was the only Chinese automaker invited to speak at CVPR WAD, where it shared advances in autonomous driving foundation models. At its AI Day in November, XPENG unveiled VLA 2.0 architecture, which removes the “language translation” step and enables direct Visual-to-Action generation, a breakthrough that redefines the conventional V-L-A pipeline.

These accomplishments reflect XPENG’s full-stack in-house capabilities, from model architecture design and training to distillation and vehicle deployment. Looking ahead, XPENG remains committed to achieving L4 level autonomous driving to accelerate the integration of physical AI systems into vehicles, with the goal of delivering safe, efficient, and comfortable intelligent driving experiences to users around the world.

About XPENG
XPENG is committed to leading the transformation of future mobility through technological exploration, positioning itself as “Explorer of Future Mobility”. Headquartered in Guangzhou, China, the company operates R&D centers in Beijing, Shanghai, Shenzhen, Zhaoqing, and Yangzhou, and has established intelligent manufacturing bases in Zhaoqing and Guangzhou.

XPENG pursues a global strategy for research, development, and sales, with an R&D center in the United States and subsidiaries across multiple European countries. The company adheres to full-stack in-house development of intelligent driver-assistance software and the development of core hardware, delivering an exceptional intelligent driving and riding experience for users.

On August 27, 2020, XPENG officially listed on the New York Stock Exchange (NYSE: XPEV), raising funds in an IPO that set a record at the time for the global new energy vehicle industry. On July 7, 2021, the company listed on the Hong Kong Stock Exchange (HKEX: 9868), becoming the first Chinese new-energy automaker to achieve dual primary listings in both Hong Kong and New York.

For more information, please visit https://www.xpeng.com/.

Contacts:
For Media Enquiries: Alison Liang, XPENG PR Department
Email: liangrq3@xiaopeng.com 

SHANGRAO, China, Dec. 29, 2025 /PRNewswire/ — JinkoSolar Holding Co., Ltd. (“JinkoSolar” or the “Company”) (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that all shareholders resolutions proposed at the Company’s 2025 annual general meeting held today were duly passed. Specifically, the Company’s shareholders passed the following ordinary resolutions approving:

1. The re-election of Mr. Haiyun Cao as a director of the Company;
2. The re-election of Mr. Wing Keong Siew as an independent director of the Company;
3. The ratification of the appointment of PricewaterhouseCoopers Zhong Tian LLP as auditors of the Company for the fiscal year of 2025;
4. The authorization of the directors of the Company to determine the remuneration of the auditors of the Company; and
5. The authorization of each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions 1 to 4 as such director, in his or her absolute discretion, thinks fit.

 About JinkoSolar Holding Co., Ltd.

JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world. JinkoSolar distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, Netherlands, Poland, Austria, Switzerland, Greece and other countries and regions.

JinkoSolar had over 10 productions facilities globally, over 20 overseas subsidiaries in Japan, South Korea, Vietnam, India, Turkey, Germany, Italy, Switzerland, the United States, Mexico, and other countries, and a global sales network with sales teams in China, the United States, Canada, Brazil, Chile, Mexico, Italy, Germany, Turkey, Spain, Japan, the United Arab Emirates, Netherlands, Vietnam and India, as of September 30, 2025.

To find out more, please see: www.jinkosolar.com

For investor and media inquiries, please contact:

In China:

Ms. Stella Wang
JinkoSolar Holding Co., Ltd.
Tel: +86 21-5180-8777 ext.7806
Email: ir@jinkosolar.com 

Mr. Christian Arnell
Christensen
Tel: +852 2117 0861
Email: christian.arnell@christensencomms.com

In the U.S.:

Ms. Linda Bergkamp
Christensen, Scottsdale, Arizona
Tel: +1-480-614-3004
Email: linda.bergkamp@christensencomms.com